companydata.dkAdaptVac ApS: Financial statements 2019
CVR: 38732730
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 1,417,122 and a net result of DKK -185,145 compared with DKK 333,539 the year before. That is an increase of 228.1% compared with the year before. Equity amounted to DKK -121,627. The company had 3 employees in the financial year.
- Gross Profit
- 1,417,122 kr.
- Profit/Loss
- -185,145 kr.
- Equity
- -121,627 kr.
- Total Assets
- 1,372,078 kr.
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
| 2018 | - | 432 t. | 334 t. | 64 t. | 0 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
AdaptVac ApS has published its annual report for 2018. Gross profit came to DKK 431,961, and the net result was DKK 333,539.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.